中文名特立帕肽
英文名Teriparatide
別名特立帕肽
醋酸特立帕肽
醋酸立特帕肽
甲狀旁腺素(人)
重組人甲狀旁腺 激素1-34
醋酸特立帕肽|PTH (1-34) (HUMAN)
醋酸特立帕肽 TERIPARATIDEACETATE
英文別名Teriparatide
TERIPARATIDE
PTH (HUMAN, 1-34)
PTH (1-34) (HUMAN)
Teriparatide acetate
PARATHYROID HORMONE (HUMAN, 1-34)
PARATHYROID HORMONE (1-34), HUMAN
SVSEIWLRKKLQDVHNF
CAS52232-67-4
EINECS640-978-1化學(xué)式C172H278N52O47S2
分子量3890.49792InChIInChI=1/C181H291N55O51S2/c1-21-96(18)146(236-160(267)114(48-53-141(250)251)212-174(281)132(84-239)232-177(284)143(93(12)13)233-147(254)103(185)82-237)178(285)216-111(45-50-134(187)241)155(262)219-119(65-90(6)7)163(270)213-116(55-62-289-20)158(265)224-124(71-100-79-196-86-203-100)167(274)226-126(73-135(188)242)169(276)217-117(63-88(2)3)148(255)201-81-138(245)205-105(39-27-30-56-182)149(256)223-123(70-99-78-195-85-202-99)166(273)221-121(67-92(10)11)164(271)225-128(75-137(190)244)171(278)231-131(83-238)173(280)214-115(54-61-288-19)157(264)210-112(46-51-139(246)247)153(260)208-109(43-34-60-199-181(193)194)159(266)234-144(94(14)15)175(282)215-113(47-52-140(248)249)156(263)222-122(69-98-77-200-104-38-26-25-37-102(98)104)165(272)220-120(66-91(8)9)161(268)209-108(42-33-59-198-180(191)192)151(258)206-106(40-28-31-57-183)150(257)207-107(41-29-32-58-184)152(259)218-118(64-89(4)5)162(269)211-110(44-49-133(186)240)154(261)228-129(76-142(252)253)172(279)235-145(95(16)17)176(283)229-125(72-101-80-197-87-204-101)168(275)227-127(74-136(189)243)170(277)230-130(179(286)287)68-97-35-23-22-24-36-97/h22-26,35-38,77-80,85-96,103,105-,200,237-239H,21,27-34,39-76,81-84,182-185H2,1-20H3,(H2,186,240)(H2,187,241)(H2,188,242)(H2,189,243)(H2,190,244)(H,195,202)(H,196,203)(H,197,204)(H,201,255)(H,205,245)(H,206,258)(H,207,257)(H,208,260)(H,209,268)(H,210,264)(H,211,269)(H,212,281)(H,213,270)(H,214,280)(H,215,282)(H,216,285)(H,217,276)(H,218,259)(H,219,262)(H,220,272)(H,221,273)(H,222,263)(H,223,256)(H,224,265)(H,225,271)(H,226,274)(H,227,275)(H,228,261)(H,229,283)(H,230,277)(H,231,278)(H,232,284)(H,233,254)(H,234,266)(H,235,279)(H,236,267)(H,246,247)(H,248,249)(H,250,251)(H,252,253)(H,286,287)(H4,)(H4,)熔點(diǎn)>205oC (dec.)溶解度DMSO (微溶) 、水 (微溶)存儲(chǔ)條件?20°C外觀粉末顏色White to Off-White體內(nèi)研究Trabecular bone calcium and dry weight of the distal femurincreased significantly in Teriparatide-treated animals. Theincrease in trabecular calcium compared with vehicle controloccurred as early as 1 week after initiation of treatment with a35% and 45% increase, respectively, for 10 μg/kg and 40 μg/kgTeriparatide. Similar results were observed for trabecular dryweight. After 4 weeks of treatment with 10 mg/kg or 40 mg/kgTeriparatide, trabecular calcium increased significantly by 70% and123%, respectively, compared with the vehicle and by 73%. The4-week Teriparatide administration increase the pore ratio, number,and density as well as the cortical area, thickness, and bonemineral content (BMC), without significant influencing thevolumetric bone mineral density (BMD). The 4-week Teriparatideadministration + 8-week vehicle administration decrease the poreratio, number, and density as well as the cortical area andthickness, compared with the 4-week Teriparatide administration,but the pore ratio, cortical area, and thickness are still highercompared with the 12-week vehicle administration. The 4-weekTeriparatide administration + 8-week higherdose IBN administrationincrease the cortical area, thickness, BMC, and volumetric BMD anddecrease the pore ratio, but not the pore number or density,compared with the 4-week Teriparatide administration + 8-weekvehicle administration.WGK Germany3RTECSS海關(guān)編號(hào)2937190000
醋酸特立帕肽 - 配置溶液濃度參考 1mg5mg10mg1mM0.243 ml1.214 ml2.429 ml5mM0.049 ml0.243 ml0.486 ml10mM0.024 ml0.121 ml0.243 ml5mM0.005 ml0.024 ml0.049 ml